



Communication Address:

Solara Active Pharma Sciences Limited
2nd Floor, Admin Block
27, Vandaloor Kelambakkam Road,
Keelakottaiyur Village, Melakottaiyur (Post)
Chennai – 600 127, India
Tel : +91 44 43446700
Fax : +91 44 47406190
E-mail : investors@solara.co.in
www.solara.co.in

October 23, 2024

The BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001

The National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 541540,890202

Scrip Code: SOLARA, SOLARAPP

Dear Sir/Madam,

Sub: Newspaper advertisement - Unaudited Financial Results for the quarter ended September 30, 2024

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith copies of newspaper advertisement published on October 22, 2024, in the 'Business Standard' and 'Pratahkal' providing extract of the Unaudited Financial Results of the Company for the quarter ended September 30, 2024.

These are also being made available on the Company's website at <https://solara.co.in/investor-relations/newspaper-publications>

This is for your information and record.

Thanking you,

Yours faithfully,
For **Solara Active Pharma Sciences Limited**

S. Murali Krishna
Company Secretary

Encl.: as above

NOTICE CUM ADDENDA

DSP

ASSET MANAGERS

DSP Equity & Bond Fund
(An open ended hybrid scheme investing predominantly in equity and equity related instruments)

This product is suitable for investors who are seeking*:	Scheme Riskometer	Benchmark Riskometer
<ul style="list-style-type: none"> Capital growth and income over a long-term investment horizon Investment primarily in equity/equity-related securities, with balance exposure in money market and debt securities <p>*Investors should consult their financial advisers if in doubt about whether the Scheme is suitable for them.</p>	<p>RISKOMETER INVESTORS UNDERSTAND THAT THEIR PRINCIPAL WILL BE AT VERY HIGH RISK</p>	<p>As per AMFI Tier I Benchmark: CRISIL Hybrid 35+65 – Aggressive Index</p> <p>RISKOMETER INVESTORS UNDERSTAND THAT THEIR PRINCIPAL WILL BE AT VERY HIGH RISK</p>

(For latest Riskometers, investors may refer on the website of the Fund viz. www.dspim.com)

Unit holders are requested to update their PAN, KYC, email address, mobile number, nominee details with AMC and are also advised to link their PAN with Aadhaar Number. Further, Unit holders can view the Investor Charter available on website of the Fund as well as check for any unclaimed redemptions or Income Distribution cum Capital Withdrawal (IDCW) payments.

Place: Mumbai
Date: October 22, 2024

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

Page 3 of 3

CROWN LIFTERS LIMITED						
CIN: L74210MH2002PLC138439						
Registered Office: 104, Raheja Plaza Premises Co-Op Soc. Ltd., Shah Industrial Estate, Veera Desai Rd, Andheri (W) Mumbai - 400053.						
Tel No: +91 +91 22 4006 2829; E-mail: cs.cll@crownlifters.com ; Website: www.crownlifters.com						
Statement of Financial Results for the Quarter Ended on September 30th, 2024 (Rs. in Lakhs)						
Sr. No	Particulars	Quarter Ended			Year Ended	
		30-09-2024 (Un-Audited)	30-06-2024 (Un-Audited)	30-09-2023 (Un-Audited)	30-09-2023 (Un-Audited)	31-03-2024 (Audited)
1	Total Income from Operations (Net)	798.51	793.30	539.92	1591.81	2886.78
2	Net Profit / (Loss) for the period (before tax & Exceptional Items)	284.76	233.90	105.15	518.66	738.00
3	Net Profit / (Loss) for the Period before Tax (after Exceptional Items)	285.21	1461.94	105.15	1747.15	738.04
4	Net Profit / (Loss) for the Period after Tax (after Exceptional Items)	212.80	1095.66	105.15	1308.46	550.79
5	Total Comprehensive Income [Comprising Profit / (Loss) after Tax and Other Comprehensive Income after Tax]	212.80	1095.66	105.15	1308.46	550.79
6	Equity Share Capital	1122.33	1122.33	1041.00	1122.33	1122.33
7	Reserves excluding Revaluation Reserve as at Balance Sheet date	3793.42	3580.62	1294.30	3793.42	2484.96
8	Earnings Per Share (of Rs. 10 each, in Rs.)					
	Basic	1.90	9.76	1.01	11.66	5.28
	Diluted	1.90	9.76	1.01	11.66	5.28

NOTES:
1. The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015. The full format of the financial result is available on the Stock Exchange websites: www.nseindia.com & company's website: www.crownlifters.com.

On behalf of the Board of Directors
CROWN LIFTERS LIMITED
SD/-
Mr. Nizar Nooruddin Rajwani - Director & Chief Financial Officer
DIN: 03312143

Place : Mumbai
Date : 21.10.2024

MAHINDRA MANULIFE INVESTMENT MANAGEMENT PRIVATE LIMITED	
Corporate Identity Number: U65900MH2013PTC244758	
Registered Office : "A" Wing, 4 th Floor, Mahindra Towers, Dr. G.M Bhosale Marg, P.K. Kurne Chowk, Worli, Mumbai 400 018	
Corporate Office: Unit No. 204, 2 nd Floor, Amiti Building, Piramal Agastya Corporate Park, LBS Road, Kamani Junction, Kuria (West), Mumbai - 400 070.	
Tel: 1800 4196244; website: www.mahindramanulife.com ; email id: mfinvestors@mahindra.com	
NOTICE NO. 32/2024	
Notice is hereby given to the Investor(s)/Unit holder(s) of the scheme(s) of Mahindra Manulife Mutual Fund ("the Fund") that in accordance with Regulation 59 of SEBI (Mutual Funds) Regulations, 1996 read with Clause 5.3 of SEBI Master Circular No. SEBI/HO/IMD/IMD-PoD-1/P/CIR/2024/90 dated June 27, 2024, the unaudited half yearly financial results of all the scheme(s) of Mahindra Manulife Mutual Fund ("the Fund") for the period ended September 30, 2024, is hosted on the Fund's website www.mahindramanulife.com in a user - friendly and downloadable format.	
Investor(s)/Unit holder(s) are requested to take a note of the same.	
For Mahindra Manulife Investment Management Private Limited	
Place: Mumbai	SD/-
Date: October 21, 2024	Authorised Signatory
Mutual Fund investments are subject to market risks, read all scheme related documents carefully.	

50 years of opinion that shapes opinions.

50 Years of Insight

Mukka Proteins Limited	
MUKKA PROTEINS LIMITED	
Regd. Office: Mukka Corporate House, Door No. 18-2-16/4, First Cross, NG Road, Attavara, Dakshina Kannada, Mangaluru - 575001, Karnataka.	
Tel: +918244252889 Email: investors@mukkaproteins.com	
Website: www.mukkaproteins.com CIN: L05004KA2010PLC055771	
INFORMATION REGARDING THE EXTRA-ORDINARY GENERAL MEETING TO BE HELD THROUGH VIDEO CONFERENCING/OTHER AUDIO-VISUAL MEANS	
Members may please note that the an Extra-Ordinary General Meeting ("EGM") of Mukka Proteins Limited ("the Company") will be held on Saturday, 16th day of November 2024 at 03:00 P.M (IST), through Video Conferencing ("VC")/Other Audio Visual Means ("OAVM") in compliance with the applicable provisions of the Companies Act, 2013 read with rules framed thereunder and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in accordance with the General Circular No. 14/2020 dated April 8, 2020, General Circular No. 17/2020 dated April 13, 2020, General Circular No. 20/2020 dated May 5, 2020, General Circular No. 02/2021 dated January 13, 2021, General Circular No. 19/2021 dated December 08, 2021 and General Circular No. 21/2021 dated December 14, 2021 and General Circular No. 2/2022 dated May 05, 2022 and General Circular No. 10/2022 dated December 28, 2022 and General Circular No. 09/2023 dated September 25, 2023 and General Circular No. 09/2024 dated September 19, 2024 issued by the Ministry of Corporate Affairs ("MCA") and SEBI Circular no. SEBI/HO/CFD/CFD-PoD-2/P/ CIR/2023/167 dated October 7, 2023 and Circular No. SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/P/CIR/2024/133 dated October 3, 2024 issued by Securities and Exchange Board of India ("SEBI") (hereinafter collectively referred to as "Circulars"). The deemed venue for the EGM shall be the Registered Office of the Company. As the EGM is being convened through VC/OAVM, physical presence of the Members at the venue is not required.	
In compliance with the above referred Circulars, the Notice of the EGM will be sent, in due course, only by e-mail to those Members, whose e-mail address is registered with their Depository Participants ("DP"). Members may take note that the aforesaid documents will also be available on the Company's website at www.mukkaproteins.com , website of BSE Limited at www.bseindia.com and website of National Stock Exchange of India Limited at www.nseindia.com .	
Manner of casting votes and attending EGM:	
Remote e-voting (prior to EGM) and e-voting (during the EGM) facility will be provided to all Members to cast their votes on all the resolutions set out in Notice of the EGM. Detailed instructions for remote e-voting and e-voting during the EGM will be provided in Notice of the EGM.	
Members can join and participate in the EGM through VC/OAVM facility only. Members participating through VC/OAVM facility shall be counted for the purpose of reckoning quorum under Section 103 of the Act. Detailed instructions for joining the EGM through VC/OAVM will be provided in the Notice of the EGM.	
Manner of registering/updating e-mail address and other details:	
Members holding shares in Demat form are advised to register/update the particulars of their e-mail address, bank account, change of postal address and mobile number etc. to their respective DPs. The e-mail address registered with the DPs will be used for sending all the communications.	
The above information is being issued for the information and benefit of all the Members of the Company.	
For and on behalf of the Board of Directors Mukka Proteins Limited SD/- Kalandan Mohammed Haris Managing Director & CEO	
Place : Mangaluru	
Date : 21-10-2024	

SOLARA Active Pharma Sciences							
SOLARA ACTIVE PHARMA SCIENCES LIMITED							
CIN: L24230MH2017PLC291636							
Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 703.							
Address: 2nd Floor, Admin Block 27, Vandaloor kelambakkam Road, Keelakottaiyur Village, Chennai 600 127.							
EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2024 (Rs. in Crores except per share data)							
Sl. No.	Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for the current period ended	Year to date figures for the previous period ended	Previous Financial Year ended
		30.09.2024 UNAUDITED	30.06.2024 UNAUDITED	30.09.2023 UNAUDITED	30.09.2024 UNAUDITED	30.09.2023 UNAUDITED	31.03.2024 AUDITED
Continuing operations:							
1	Total income from operations	346.95	363.49	425.24	710.44	777.55	1,288.92
2	Net Profit for the period before tax (before exceptional items)	8.01	(13.46)	(11.84)	(5.45)	(41.20)	(298.25)
3	Net Profit for the period before tax (after exceptional items)	8.01	(13.46)	(17.06)	(5.45)	(46.42)	(488.42)
4	Net Profit for the period after tax	8.01	(13.46)	(17.06)	(5.45)	(36.17)	(566.96)
5	Other Comprehensive Income for the period	1.68	(0.01)	0.23	1.67	0.23	0.49
6	Total Comprehensive Income for the period (4 + 5)	9.69	(13.47)	(16.83)	(3.78)	(35.94)	(566.47)
7	Equity Share Capital	40.21	40.21	36.00	40.21	36.00	36.00
8	Other Equity						897.91
9	Earnings Per Share (of Rs. 10/- each) (for continuing operations) -						
	Basic (Rs.)	2.54	(3.50)	(4.47)	(0.96)	(9.47)	(148.27)
	Diluted (Rs.)	2.54	(3.50)	(4.47)	(0.96)	(9.47)	(148.27)

Notes:
1. The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the websites of the NSE Limited (www.nseindia.com), BSE Limited (www.bseindia.com) and at the Company's website (www.solara.co.in)
2. The above consolidated financial results of Solara Active Pharma Sciences Limited ("the Parent" or the Company) and its subsidiaries (together referred to as "the group") as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on October 21, 2024. The results for the quarter and six months ended September 30, 2024 has been reviewed by Deloitte Haskins & Sells LLP, the statutory auditors of the Company. The statutory auditors of the Company have expressed an unmodified conclusion in respect of limited review for the quarter and six months ended September 30, 2024.
3. The Parent, vide its letter of offer dated May 09, 2024 offered upto 1,19,98,755 Equity shares of face value of Rs.10/- each at a price of Rs. 375/- per Equity share (including Share premium of Rs. 365/- per Equity share) for an amount aggregating Rs. 449.95 crores to the existing share holders of the Parent on right basis in the ratio of One Equity share for every three Equity shares held by the Equity shareholders on the record date i.e May 15, 2024. Rights issue has been done in accordance with Section 62(1)(a) of the Companies Act, 2013 and other applicable laws. The Parent has allotted 1,19,98,755 Nos. of partly paid up equity shares on 19 June, 2024.
Accordingly, the paid-up equity share capital of the Company has increased from Rs. 36,00,52,670/- divided into 3,60,05,267 fully paid up Equity Shares of face value of Rs. 10/- each and 1,19,98,755 partly paid up Equity Shares having face value of Rs. 10 each with the Paid up value of Rs. 3.50/- per Share. Pursuant to the Rights issue, earnings per share (EPS) in respect of previous year / periods have been adjusted as per Indian Accounting Standard 33 "Earnings per share", prescribed under Section 133 of the Companies Act, 2013.

For and on behalf of board
SD/-
Poorvank Purohit - MD & CEO
DIN: 10158900

Place : Bengaluru
Date : October 21, 2024